Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-628-5 | CAS number: 108-90-7
Repeated dose toxicity: other routes
Administrative data
- Endpoint:
- sub-chronic toxicity: other route
- Type of information:
- experimental study
- Adequacy of study:
- other information
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- other: Only short abstract available
Data source
Reference
- Title:
- No information
- Author:
- Knapp, W.K. et al. (1971): Toxicol. Appl. Pharmacol. 19, 393
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Monochlorobenzene has been administered by oral route once a day (via capsule) to dogs 5 days per week over a 93-day period. Clinical and gross and/or microscopic examinations have been performed.
- GLP compliance:
- not specified
- Limit test:
- yes
Test material
- Reference substance name:
- Chlorobenzene
- EC Number:
- 203-628-5
- EC Name:
- Chlorobenzene
- Cas Number:
- 108-90-7
- Molecular formula:
- C6H5Cl
- IUPAC Name:
- chlorobenzene
- Details on test material:
- IUCLID4 Test substance: no data
Constituent 1
Test animals
- Species:
- dog
Administration / exposure
- Route of administration:
- other: oral administration via capsule
- Duration of treatment / exposure:
- 93 d
- Frequency of treatment:
- 1 x/d, 5 d/w
Doses / concentrations
- Remarks:
- Doses / Concentrations:
27.25, 54.5 or 272.5 mg/kg bw/d
- Details on study design:
- Post-exposure period: no
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- not specified
- Histopathological findings: neoplastic:
- not specified
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 54.5 mg/kg bw/day
- Sex:
- not specified
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Year: 1971 (unclear if "Year of test guideline" or "Year of study completion".)
RM-Freetext:
Mortality: 4 out of 8 of the high dose after 14 - 21 daily
doses; clinical studies prior to death revealed an increase
in immature leucocytes, low blood sugar, elevated serum
glutamic-pyruvic transaminase and alkaline phosphatase, and
in some dogs, increases in total bilirubin and total
cholesterol. At the high level, there were gross and/or
microscopic pathology in liver, kidney, gastrointestinal
mucosa, and hematopoietic tissue of the dogs which died and,
less extensively, in the dogs which were sacrificed at the
end of the exposure period. No consistent signs of chloro-
benzene effects were evident in the dogs at the intermediate
and low levels.
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
